ConvaTec Selects Veeva Vault CDMS for Biomarker Study in Wound Infections

Rhea-AI Summary

Veeva Systems (NYSE: VEEV) announced that ConvaTec has chosen Veeva Vault CDMS for electronic data capture in a study focused on detecting wound infections. This proof-of-concept study will evaluate the effectiveness of a combination of biomarkers—wound pH, human neutrophil elastase (HNE), and myeloperoxidase (MPO)—to detect infections. The international study aims to enroll 75 to 90 subjects over approximately 20 weeks. Veeva MedTech supports ConvaTec's efforts with its unified data management solution.

Positive

• ConvaTec selected Veeva Vault CDMS for a significant clinical study, enhancing Veeva's market position.
• The study focuses on innovative biomarker technology, potentially leading to advancements in wound care.

Negative

• None.

PLEASANTON, Calif., Sept. 23, 2021 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that ConvaTec, a global medical products company providing therapies focused on the management of chronic conditions, has selected Veeva Vault CDMS to provide electronic data capture (EDC), coding, and data cleaning for their upcoming study on the detection of wound infections.

To aid accurate and timely detection of wound infection in clinical practice, ConvaTec and partners have developed a new infection biomarker detection technology based on the combined measurement of the following three biomarkers: wound pH, activity of human neutrophil elastase (HNE), and myeloperoxidase (MPO) host enzymes. This proof-of-concept study will explore the effectiveness of a novel combination of biomarkers, pH, HNE, and MPO, in detecting wound infection.

A secondary objective of the trial is to explore the relationship between molecular microbiological analysis of swab samples and wound biopsies with the biomarkers pH, HNE, and MPO.

This is a multi-center, international, analytical performance study expected to take approximately 20 weeks to complete and aims to enroll between 75 and 90 subjects.

Veeva MedTech is proud to support companies like ConvaTec with Vault CDMS, a unified data management solution for clinical data capture, cleaning, and coding. For more information on Vault CDMS, visit veeva.com/VaultCDMS.

Additional Information
Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veevasystems on Twitter: twitter.com/veevasystems 

About Veeva Systems
Veeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,100 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.

Contact:
Deivis Mercado Veeva Systems 925-226-8821 deivis.mercado@veeva.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/convatec-selects-veeva-vault-cdms-for-biomarker-study-in-wound-infections-301383514.html

SOURCE Veeva Systems

FAQ

What is Veeva's recent announcement regarding ConvaTec?

Veeva announced that ConvaTec has selected Veeva Vault CDMS for its upcoming study on detecting wound infections.

What biomarkers will be used in ConvaTec's wound infection study?

The study will utilize wound pH, human neutrophil elastase (HNE), and myeloperoxidase (MPO) as biomarkers.

How long is ConvaTec's study using Veeva Vault CDMS expected to last?

The study is expected to take approximately 20 weeks to complete.

How many subjects will be enrolled in the wound infection study?

The study aims to enroll between 75 and 90 subjects.

What role does Veeva MedTech play in ConvaTec's study?

Veeva MedTech supports ConvaTec by providing its Vault CDMS for clinical data management.